Madrigal Pharmaceuticals is positioning itself for significant growth in the metabolic dysfunction-associated steatohepatitis (MASH) arena through a substantial licensing agreement. With a deal valued at up to $4.4 billion with Chinese biotech firm Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals, Madrigal aims to broaden its therapeutic offerings.
Strategic Investment in siRNA Technology
Under the terms of the agreement, Madrigal will pay an upfront fee of $60 million for the rights to develop and commercialize six preclinical therapies based on silent interfering RNA (siRNA). These therapies target specific genes responsible for the disease’s progression, offering a precision approach to MASH treatment. The partnership allows Madrigal to explore the potential of advanced siRNA technology, enhancing its therapeutic pipeline.
Milestone Payments and Future Opportunities
In addition to the upfront payment, the agreement includes provisions for Ribo to receive up to $4.4 billion in milestone payments related to development, regulatory approvals, and commercial sales. Ribo is also in line for potential royalties on sales from the new candidates. This financial structure underscores the potential value that both parties see in the collaboration.
Importantly, Madrigal retains the option to license additional early-stage development programs from Ribo, which includes a range of bispecific siRNA candidates. This flexibility could lead to further innovations in the treatment of MASH and related liver diseases.
Synergistic Potential with Rezdiffra
A pivotal aspect of the collaboration is the integration of the newly licensed siRNA candidates with Madrigal’s existing therapy, Rezdiffra (resmetirom), which has already received approval for the treatment of MASH. Madrigal’s chief medical officer, David Soergel, emphasized that siRNAs are highly targeted to the liver, thus allowing for a precision approach to address multiple genes implicated in MASH pathology. By combining siRNA technology with Rezdiffra, Madrigal aims to develop genetically targeted therapies that address unmet medical needs.
Leveraging Innovative Platforms
At the heart of the collaboration lies Ribo’s GalSTAR platform, which facilitates the development of RNA interference (RNAi) therapeutics aimed at genes linked to liver disease. This platform has garnered attention, with German pharmaceutical giant Boehringer Ingelheim previously securing a $2 billion deal to utilize it for liver disease therapies.
MASH Landscape and Competitive Dynamics
MASH, formerly known as nonalcoholic steatohepatitis (NASH), is characterized by fat accumulation in the liver, leading to chronic inflammation and severe complications such as cirrhosis and liver cancer. In 2024, Madrigal became the first company to secure approval for a drug specifically targeting MASH with Rezdiffra, a thyroid hormone receptor beta (THR-β) agonist.
Following this milestone, Madrigal has reinforced its commitment to MASH by acquiring Pfizer’s investigational candidate, ervogastat, for $50 million, along with two other preclinical assets aimed at the same indication. The company anticipates that combining ervogastat with Rezdiffra may yield additional clinical benefits, further bolstering its therapeutic portfolio.
Financial Performance and Market Projections
Rezdiffra has emerged as a critical revenue driver for Madrigal, generating $287.3 million in Q3 2025 alone. Projections from GlobalData indicate that Rezdiffra’s sales could surge to $6.9 billion by 2032, with the potential for blockbuster status as early as 2025.
However, competition is intensifying in the MASH market, particularly with the entry of Novo Nordisk’s Wegovy (semaglutide), a glucagon-like peptide 1 receptor agonist that received approval for MASH in August 2025. Novo Nordisk is actively expanding its presence in this domain, recently acquiring Akero, a specialist in the indication, for up to $5.2 billion.
Future Outlook for the MASH Market
Analysts forecast that the MASH market will experience substantial growth, projected to reach $20.3 billion by 2032, marking a compound annual growth rate (CAGR) of 38.2% from 2022. This burgeoning market underscores the strategic significance of Madrigal’s recent licensing deal and its commitment to pioneering advancements in MASH therapies.
Conclusion
Madrigal Pharmaceuticals’ ambitious licensing agreement with Ribo Life Science not only enhances its MASH pipeline but also positions the company favorably in a rapidly evolving market. As the company integrates siRNA technology with its existing therapies, it stands to address significant unmet needs in liver disease treatment, potentially reshaping the landscape of MASH therapeutics. The future looks promising for Madrigal as it navigates competitive dynamics and leverages innovative platforms for growth.
- Madrigal Pharmaceuticals has secured a $4.4 billion licensing deal with Ribo Life Science.
- The deal focuses on six preclinical siRNA therapies targeting MASH.
- Madrigal’s Rezdiffra, already approved for MASH, may benefit from integration with new siRNA candidates.
- The MASH market is projected to reach $20.3 billion by 2032.
- Competition is intensifying, with notable players like Novo Nordisk entering the space.
Read more → www.pharmaceutical-technology.com